About FUTR BIO

FUTR BIO develops next-generation mRNA vaccines utilizing proprietary technology that incorporates natural untranslated regions (UTRs) and molecular boosters to enhance immune responses against infectious diseases and cancer. Their single-dose vaccines aim to provide faster and more durable protection for both humans and animals.

<problem> Current mRNA vaccines often require multiple doses and may not elicit sufficiently durable or robust immune responses, particularly against rapidly evolving pathogens and complex diseases like cancer. Existing vaccine technologies may also lack the flexibility to be rapidly adapted to new variants or personalized for individual patients. </problem> <solution> FUTR BIO is developing next-generation mRNA vaccines designed to enhance immune responses and provide faster, more durable protection against infectious diseases and cancer. Their proprietary technology incorporates natural untranslated regions (UTRs) and molecular boosters to improve mRNA stability, translation efficiency, and immunogenicity. This approach aims to create single-dose vaccines that induce strong, long-lasting immunity by fine-tuning the mammalian immune system. The platform is designed to be adaptable, allowing for rapid development of vaccines against emerging threats and personalized immunotherapies. </solution> <features> - Utilizes natural UTRs to enhance mRNA stability and translational efficiency - Incorporates molecular boosters to stimulate stronger immune responses - Designed for single-dose administration to improve patient compliance and reduce healthcare costs - Flexible platform allows for rapid adaptation to new viral variants and personalized vaccine development - Focus on both prophylactic vaccines for infectious diseases and therapeutic vaccines for cancer </features> <target_audience> The primary target audience includes individuals at risk of infectious diseases, cancer patients, and healthcare providers seeking more effective and convenient vaccine options. </target_audience>

What does FUTR BIO do?

Where is FUTR BIO located?

FUTR BIO is based in Florianópolis, Brazil.

When was FUTR BIO founded?

FUTR BIO was founded in 2022.

Location

Florianópolis, Brazil

Founded

2022

Employees

3 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

FUTR BIO

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

futr.bio 300+

Founded 2022 – Florianópolis, Brazil

Funding

No funding information available.

Team (<5)

No team information available.

Company Description

Problem

Current mRNA vaccines often require multiple doses and may not elicit sufficiently durable or robust immune responses, particularly against rapidly evolving pathogens and complex diseases like cancer. Existing vaccine technologies may also lack the flexibility to be rapidly adapted to new variants or personalized for individual patients.

Solution

FUTR BIO is developing next-generation mRNA vaccines designed to enhance immune responses and provide faster, more durable protection against infectious diseases and cancer. Their proprietary technology incorporates natural untranslated regions (UTRs) and molecular boosters to improve mRNA stability, translation efficiency, and immunogenicity. This approach aims to create single-dose vaccines that induce strong, long-lasting immunity by fine-tuning the mammalian immune system. The platform is designed to be adaptable, allowing for rapid development of vaccines against emerging threats and personalized immunotherapies.

Features

Utilizes natural UTRs to enhance mRNA stability and translational efficiency

Incorporates molecular boosters to stimulate stronger immune responses

Designed for single-dose administration to improve patient compliance and reduce healthcare costs

Flexible platform allows for rapid adaptation to new viral variants and personalized vaccine development

Focus on both prophylactic vaccines for infectious diseases and therapeutic vaccines for cancer

Target Audience

The primary target audience includes individuals at risk of infectious diseases, cancer patients, and healthcare providers seeking more effective and convenient vaccine options.